InvestSMART

Bionomics Limited (ASX: BNO) - Announcements

DELISTED - Current share price for BNO : $0.010

ASX company news and announcements for Bionomics Limited (BNO) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bionomics Limited (BNO) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bionomics Limited (BNO), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bionomics Limited (BNO)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Change in substantial holding 5 Mar 2021 12:49PM $0.285 $0.010 fallen by 96.49%
- Change in substantial holding 4 Mar 2021 9:19AM $0.325 $0.010 fallen by 96.92%
- Appendix 2A 2 Mar 2021 3:22PM $0.355 $0.010 fallen by 97.18%
- Cleansing Notice 2 Mar 2021 2:37PM $0.360 $0.010 fallen by 97.22%
- Completion of Placement 2 Mar 2021 2:19PM $0.365 $0.010 fallen by 97.26%
- Half Yearly Report and Accounts 26 Feb 2021 2:38PM $0.360 $0.010 fallen by 97.22%
- Change in substantial holding 24 Feb 2021 10:03AM $0.360 $0.010 fallen by 97.22%
- Positive BNC210 PK Results for Solid Dose Formulation 22 Feb 2021 9:35AM $0.350 $0.010 fallen by 97.14%
- Bionomics and EmpathBio Joint Feasibility Assessment 17 Feb 2021 8:10AM $0.235 $0.010 fallen by 95.74%
- Notification of Change in Auditor 12 Feb 2021 9:33AM $0.250 $0.010 fallen by 96%
- Proposed issue of Securities - BNO 9 Feb 2021 10:35AM $0.230 $0.010 fallen by 95.65%
- $16 Million Capital Raise to Progress BNC210 PTSD Trial 9 Feb 2021 9:17AM $0.220 $0.010 fallen by 95.45%
- Response to ASX Price Query 5 Feb 2021 12:40PM $0.203 $0.010 fallen by 95.06%
- Appendix 4C - quarterly 29 Jan 2021 9:40AM $0.150 $0.010 fallen by 93.33%
- BNC105 / Nivolumab Treatment Completed in Phase 2 Trial 20 Jan 2021 10:19AM $0.160 $0.010 fallen by 93.75%
- Publication of Positive BNC210 Phase 2a Data in GAD Patients 18 Jan 2021 10:26AM $0.165 $0.010 fallen by 93.94%
- BNO Presenting at H.C. Wainwright BioConnect 2021 Conference 7 Jan 2021 2:38PM $0.150 $0.010 fallen by 93.33%
- BNO Initiates 7-Day Dosing Pharmacokinetic Study of BNC210 4 Jan 2021 9:53AM $0.145 $0.010 fallen by 93.10%
- Lapse of Employee Share Options & Warrants 18 Dec 2020 11:42AM $0.135 $0.010 fallen by 92.59%
- Appendix 3Y 24 Nov 2020 4:45PM $0.125 $0.010 fallen by 92%
- Final Director's Interest Notice 20 Nov 2020 1:38PM $0.130 $0.010 fallen by 92.31%
- Results of Meeting 20 Nov 2020 12:39PM $0.130 $0.010 fallen by 92.31%
- Executive Chairmans 2020 AGM Presentation 20 Nov 2020 9:47AM $0.130 $0.010 fallen by 92.31%
- Bionomics Licenses Drug Candidate BNC101 to Carina Biotech 19 Nov 2020 9:38AM $0.120 $0.010 fallen by 91.67%
- BNO Presenting at Neuropsychiatric Drug Development Summit 9 Nov 2020 1:31PM $0.115 $0.010 fallen by 91.30%

176 - 200 of 801 results

Page 8 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.